LSE : 0OB3.L

Valneva SE

$2.09675 EUR

-$0.03 (-1.56%)

Volume
22.67K
Average Volume
61.82K
Market Capitalization
$365.43M
P/E Ratio
-2.60
Dividend Yield
0.00%
Price Target
Year High
$7.84
Year Low
$2.04
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.14
Company Overview

LSE

Thomas Lingelbach

Biotechnology

Healthcare

0OB3.L

674

FR

EUR

https://valneva.com

33 2 28 07 37 10

N/A

N/A

Liquidity Metrics

2.73

2.14

1.60

1.12

0.00

Sales & Valuation

$174.66M

2.56

4.74

-5.79

-0.40

Profitability

-$0.68

-$115.19M

-88.30%

-88.03%

-106.22%

-37.10%

P/E Metrics

-2.60

0.05

0.05

Analyst Price Target & Rating

Strong Sell

1/5

1 Analysts

%

Financial Health Scores

-2.08

1/9

$107.22M

$372.01M

$295.31M

-$102.91M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Laetitia Bachelot-Fontaine Vice President of Global Communications & European Investor Relations
Dipal Patel Chief Commercial Officer
Kendra Wergin General Counsel & Corporate Secretary
Joshua Drumm Vice President of Investor Relations
Peter Buhler Chief Financial Officer
Thomas Lingelbach President, Chief Executive Officer & Director
Petra Pesendorfer Chief People Officer
Vincent Dequenne Chief Operating Officer
Hanneke Schuitemaker Chief Scientific Officer
Juan-Carlos Jaramillo Chief Medical Officer
Poll Results

No votes yet today — be the first to share your view!

About Valneva SE (LSE:0OB3.L) Stock

Founded in Saint-Herblain, France, in 1998, Valneva SE operates as a specialized biotechnology firm, concentrating on the creation and global distribution of preventative vaccines. Its primary focus is on infectious diseases for which current medical solutions are inadequate. The company's commercialized vaccine offerings for international travelers include IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Also available is DUKORAL, an oral vaccine designed to guard against diarrhea caused by Vibrio cholera and/or enterotoxigenic Escherichia coli that produces heat-labile toxin. Valneva additionally developed VLA2001, a vaccine targeting SARS-CoV-2. In its development pipeline, Valneva is advancing VLA15, a vaccine ... candidate for Borrelia, which has successfully concluded Phase II clinical trials. Another key candidate is VLA1553, currently undergoing Phase III clinical trials for the prevention of the chikungunya virus. Valneva distributes its pharmaceutical products across a wide geographic footprint, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, other European nations, and various international markets. The company maintains significant partnerships, such as a collaboration with Pfizer, Inc. for the co-development and commercialization of its Lyme disease vaccine, and an alliance with Instituto Butantan for the development, manufacture, and distribution of a single-shot chikungunya vaccine.

Frequently Asked Questions

What is the current Valneva SE (0OB3.L) stock price?

Valneva SE(LSE:0OB3.L) stock price is $2.09675 in the last trading session. During the trading session, 0OB3.L stock reached the peak price of $7.842 while $2.035 was the lowest point it dropped to. The percentage change in 0OB3.L stock occurred in the recent session was --1.56% while the dollar amount for the price change in 0OB3.L stock was -$0.03.

0OB3.L's industry and sector of operation?

The LSE listed 0OB3.L is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of 0OB3.L?

Laetitia Bachelot-Fontaine | Vice President of Global Communications & European Investor Relations
Dipal Patel | Chief Commercial Officer
Kendra Wergin | General Counsel & Corporate Secretary
Joshua Drumm | Vice President of Investor Relations
Peter Buhler | Chief Financial Officer

How many employees does 0OB3.L have?

Number of 0OB3.L employees currently stands at 674. 0OB3.L operates from 6 rue Alain Bombard, Saint-Herblain, GE 44800, FR.

Link for 0OB3.L official website?

Official Website of 0OB3.L is: https://valneva.com

How do I contact 0OB3.L?

0OB3.L could be contacted at phone #33 2 28 07 37 10 and can also be accessed through its website. 0OB3.L operates from 6 rue Alain Bombard, Saint-Herblain, GE 44800, FR.

How many shares of 0OB3.L are traded daily?

The average number of 0OB3.L shares traded daily for last 3 months was 61.82K.

What is the market cap of 0OB3.L currently?

The market value of 0OB3.L currently stands at $365.43M with its latest stock price at $2.09675